AbbVie’s sNDA accepted for priority review for Imbruvica in combination with Gazyva for previously untreated CLL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AbbVie said FDA has accepted its supplemental New Drug Application for Priority Review for Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) in previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login